Maxim Remains Neutral on Inovio Pharma (INO) Amid INO-4212 Phase 1 Expansion; Focus is VGX-3100

August 11, 2016 12:45 PM EDT
Get Alerts INO Hot Sheet
Price: $6.98 --0%

Rating Summary:
    8 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade INO Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Maxim affirms Inovio Pharmaceuticals (Nasdaq: INO) at Hold following news of an expansion to its INO-4212 Ebola vaccine phase 1.

Analyst Jason McCarthy noted the following on Thursday:

  • Regulatory pathway. Given the lethality of the Ebola virus, the path forward likely will be via the two-animal rule. Meaning, studies of Ebolainfected primates could be used to demonstrate efficacy while safety and immunogenicity can be validated in healthy subjects. After phase I, much larger human safety studies will be required, as we have seen with J&J and partner Bavarian Nordic (BAVA - $36.93 - Buy), currently in multiple studies for their combo vaccine, including a N=1,300 phase II study.
  • Conclusion. While Inovio's infectious disease vaccines continue to make progress in Ebola, Zika and MERS, which we see as incremental positives, our focus remains on VGX-3100 and the start of the pivotal program, hopefully by YE16.

For an analyst ratings summary and ratings history on Inovio Pharmaceuticals click here. For more ratings news on Inovio Pharmaceuticals click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Add Your Comment